RxDoctor Payments Data

Anne Klassert, NP

Adult Health · Stony Brook, NYNPI 1467448985

Payments from drug & device makers

$7,185in general payments, 2019–2025

Across 195 payments — averaging $36.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Urogen Pharma, Inc.$636
  • Bayer$524
  • Astellas Pharma US Inc$416
  • Myriad Genetic Laboratories, Inc.$387
  • Coloplast$351
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,03798%
  • Education$1492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,185 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$48,975
Medicare patients
232
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron69$66,860
GemtesaVibegron24$32,003
Fosfomycin Tromethamine20$5,264
Tamsulosin Hcl195$3,569
Solifenacin Succinate27$2,911
Estradiol28$2,834
Trospium Chloride ErTrospium Chloride19$1,830
Finasteride114$1,729
Methenamine Hippurate11$1,408
Trimethoprim16$1,191
Trospium Chloride13$947
Alfuzosin Hcl ErAlfuzosin Hcl39$788
Dutasteride26$779
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip22$440
Oxybutynin Chloride ErOxybutynin Chloride30$407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$416$66,86069 claims
Sumitomo Pharma America, Inc.Gemtesa$100$32,00324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →